Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $693.5 million.

  • Keros Therapeutics' Cash & Equivalents rose 3067.51% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.5 million, marking a year-over-year increase of 3067.51%. This contributed to the annual value of $559.9 million for FY2024, which is 6908.84% up from last year.
  • Latest data reveals that Keros Therapeutics reported Cash & Equivalents of $693.5 million as of Q3 2025, which was up 3067.51% from $690.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Cash & Equivalents registered a high of $720.5 million during Q1 2025, and its lowest value of $215.6 million during Q2 2022.
  • Its 5-year average for Cash & Equivalents is $381.2 million, with a median of $322.0 million in 2023.
  • Over the last 5 years, Keros Therapeutics' Cash & Equivalents had its largest YoY gain of 36810.78% in 2021, and its largest YoY loss of 1347.77% in 2021.
  • Quarter analysis of 5 years shows Keros Therapeutics' Cash & Equivalents stood at $230.0 million in 2021, then rose by 21.3% to $279.0 million in 2022, then rose by 18.67% to $331.1 million in 2023, then skyrocketed by 69.09% to $559.9 million in 2024, then rose by 23.85% to $693.5 million in 2025.
  • Its last three reported values are $693.5 million in Q3 2025, $690.2 million for Q2 2025, and $720.5 million during Q1 2025.